Journal of the American Chemical Society
Page 8 of 9
T.; Sakata, K.; Matsunaga, S.; Kanai, M. J. Am. Chem. Soc. 2014, 136,
M.; Koch, U.; Flörke, U.; Haupt, H.-J. Z. Naturforsch. B: Chem. Sci.
5424. (f) Yoshino, T.; Ikemoto, H.; Matsunaga, S.; Kanai, M. Chem.–Eur.
J. 2013, 19, 9142. (g) Yoshino, T.; Ikemoto, H.; Matsunaga, S.; Kanai, M.
Angew. Chem., Int. Ed. 2013, 52, 2207.
1993, 48, 778. (c) Heck, R. F. J. Am. Chem. Soc. 1968, 90, 313. (d)
Murahashi, S.; Horiie, S. J. Am. Chem. Soc. 1956, 78, 4816.
1
2
3
4
5
6
7
8
(19) For selected recent examples of azobenzene C–H functionalization
with Cp*Rh(III), see: (a) Wangweerawong, A.; Bergman, R. G.; Ellman,
J. A. J. Am. Chem. Soc. 2014, 136, 8520. (b) Ryu, T.; Min, J.; Choi, W.;
Jeon, W. H.; Lee, P. H. Org. Lett. 2014, 16, 2810. (c) Wang, H.; Yu, Y.;
Hong, X.; Tan, Q; Xu, B. J. Org. Chem. 2014, 79, 3279. (d) Lian, Y.;
Hummel, J. R.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2013,
135, 12548. (e) Zhao, D.; Wu, Q.; Huang, X.; Song, F.; Lv, T.; You, J.
Chem.–Eur. J. 2013, 19, 6239. (f) Maralirajan, K.; Cheng, C.-H. Chem.–
Eur. J. 2013, 19, 6198. (g) also see reference 7a.
(20) For Co()-catalyzed alkenyl C–H functionalization, see:
Yamakawa, T.; Yoshikai, N. Org. Lett. 2013, 15, 196.
(21) Cationic Cp*Co with the non-coordinating B(C6H5)4 counterion in
combination with AgOAc is presumably successful because Ag+ and
Cp*Co2+ bind with comparable strength to acetate such that only partial
exchange occurs.
(22) For an examples where Cu(OAc)2 was beneficial for redox neutral
Rh(III)-catalyzed C–H functionalization reactions, see: (a) Liu, B.; Zhou,
T.; Li, B.; Xu, S.; Song, H.; Wang, B. Angew. Chem., Int. Ed. 2014, 53,
4191. (b) Li, B.-J.; Wang, H.-Y.; Zhu, Q.-L.; Shi, Z.-J. Angew. Chem., Int.
Ed. 2012, 51, 3948. (c) Tsai, A. S.; Brasse, M.; Bergman, R. G.; Ellman, J.
A. Org. Lett. 2011, 13, 540.
(23) For selected examples employing pivalic acid as an additive in Pd-
catalysis, see: (a) Lafrance, M.; Fagnou, K. J. Am. Chem. Soc. 2006, 128,
16496. In Cp*Rh(III)-catalysis, see: (b) Zhang, X.; Li, Y.; Shi, H.; Zhang,
L.; Zhang, S.; Xu, X.; Liu, Q. Chem. Commun., 2014, 50, 7306. (c)
Schipper, D. J.; Hutchinson, M.; Fagnou, K. J. Am. Chem. Soc. 2010, 132,
6910.
(24) Acetophenone O-methyl oxime was evaluated under the optimized
conditions but gave a mixture of products. For the Re-catalyzed synthesis
of isobenzofurans, see reference 7e.
(25) Indazole 3a was also prepared on 20 mmol scale providing a yield
of 75% (4.04 g). See Supporting Information for details.
(26) For a study demonstrating the effect of electronics on concerted-
metallation-deprotonation for related Cp*Rh(III) complexes, see: Li, L.;
Brennessel, W. W.; Jones, W. D. Organometallics, 2009, 28, 3492.
(27) To demonstrate that Co(III) is required for protio-deutero
scrambling to occur, a control reaction was run in which azobenzene 1f
was subjected to the reaction conditions in the absence of catalyst 5.
Under these conditions no protio-deutero exchange occurred. See
Supporting Information for details.
(28) The reversibility of Rh(III)-catalyzed C–H bond addition to
aldehydes has been previously demonstrated. (a) Chen, K.; Li, H.; Lei, Z.-
Q.; Li, Y.; Ye, W.-H.; Zhang, L.-S.; Sun, J.; Shi, Z.-J. Angew. Chem., Int.
Ed. 2012, 51, 9851. (b) Zhang, X.-S.; Li. Y.; Li, H.; Chen., K.; Lei, Z.-Q.;
Shi, Z.-J. Chem. Eur. J. 2012, 18, 16214. (c) Li, H.; Li, Y.; Zhang, X.-S.,
Chen, K.; Wang, X.; Shi, Z.-J. J. Am. Chem. Soc. 2011, 133, 15244.
(29) For relevant mechanistic studies demonstrated for Rh(III)-
catalysis, see: (a) reference 26; (b) Tauchert, M. E.; Incarvito, C. D.;
Rheingold, A. L.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2012,
134, 1482. (c) Li, Y.; Zhang, X.-S.; Li, H.; Wang, W.-H.; Chen, K.; Li,
B.-J.; Shi, Z.-J. Chem. Sci. 2012, 3, 1634. (d) Li, L.; Brennessel, W. W.;
Jones, W. D. J. Am. Chem. Soc., 2008, 130, 12414.
(12) For leading references on Co(0) and Co(I)-catalyzed C–H
functionalization, see: (a) Xu, W.; Yoshikai, N. Angew. Chem., Int. Ed.
2014, 53, DOI: 10.1002/anie.201408028. (b) Chen. Q.-A.; Kim, D. K.;
Dong, V. Y. J. Am. Chem. Soc. 2014, 136, 3772. (c) Zhao, C.; Crimmin,
M. R.; Toste, F. D.; Bergman, R. G. Acc. Chem. Res. 2014, 47, 517. (d)
Yamamoto, S.; Saga, Y.; Andou, T.; Matsunaga, S.; Kanai, M. Adv. Synth.
Catal. 2014, 356, 401. (e) Andou, T.; Saga, Y.; Komai, H.; Matsunaga, S.;
Kanai, M. Angew. Chem., Int. Ed. 2013, 52, 3213. (f) Punji, B.; Song, W.;
Shevchenko, G. A.; Ackermann, L. Chem.–Eur. J. 2013, 19, 10605. (g)
Song, W.; Ackermann, L. Angew. Chem., Int. Ed. 2012, 51, 8251. (h)
Ding, Z.; Yoshikai, N. Angew. Chem., Int. Ed. 2012, 51, 4698. (i) Yao, T.;
Hirano, K.; Satoh, T.; Miura, M. Angew. Chem., Int. Ed. 2012, 51, 775. (j)
Gao, K.; Yoshikai, N. Chem. Commun. 2012, 48, 4305. (k) Lee, P.-S.;
Fujita, T.; Yoshikai, N. J. Am. Chem. Soc. 2011, 133, 17283. (l) Ilies, L.;
Chen, Q.; Zeng, X.; Nakamura, E. J. Am. Chem. Soc. 2011, 133, 5221. (m)
Chen, Q.; Ilies, L.; Nakamura, E. J. Am. Chem. Soc. 2011, 133, 428. (n)
Gao, K.; Yoshikai, N. J. Am. Chem. Soc. 2011, 133, 400. (o) Gao, K.;
Yoshikai, N. Angew. Chem., Int. Ed. 2011, 50, 6888. (p) Li, B.; Wu, Z.-
H.; Gu, Y.-F.; Sun, C.-L.; Wang, B.-Q.; Shi, Z.-J. Angew. Chem., Int. Ed.
2011, 50, 1109. (q) Chen, Q.; Ilies, L.; Yoshikai, N.; Nakamura, E. Org.
Lett. 2011, 13, 3232. (r) Gao, K.; Lee, P.-S.; Fujita, T.; Yoshikai, N. J.
Am. Chem. Soc. 2010, 132, 12249. (s) Bolig, A. D.; Brookhart, M. J. Am.
Chem. Soc. 2007, 129, 14544. (t) Lenges, C. P.; White, P. S.; Brookhart,
M. J. Am. Chem. Soc. 1998, 120, 6965. (u) Lenges, C. P.; Brookhart, M. J.
Am. Chem. Soc. 1997, 119, 3165.
(13) For examples of C–H bond functionalization with Ni complexes,
see: (a) Aihara, Y.; Tobisu, M.; Fukumoto, Y.; Chatani, N. J. Am. Chem.
Soc. 2014, 136, 15509. (b) Aihara, Y.; Chatani, N. J. Am. Chem. Soc.
2014, 136, 898. (c) Muto, K.; Yamaguchi, J.; Lei, A.; Itami, K. J. Am.
Chem. Soc. 2013, 135, 16384. (d) Amaike, K.; Muto, K.; Yamaguchi, J.;
Itami, K. J. Am. Chem. Soc. 2012, 134, 13573. (e) Muto, K.; Yamaguchi,
J.; Itami, K. J. Am. Chem. Soc. 2012, 134, 169. (f) Shiota, H.; Ano, Y.;
Aihara, Y.; Fukumoto, Y.; Chatani, N. J. Am. Chem. Soc. 2011, 133,
14952. (g) Meng, L.; Kamada, Y.; Muto, K.; Yamaguchi, J.; Itami, K.
Angew. Chem., Int. Ed. 2013, 52, 10048. (h) Canivet, J.; Yamaguchi, J.;
Ban, I.; Itami, K. Org. Lett. 2009, 11, 1733. (i) Mukai, T.; Hirano, K.;
Satoh, T.; Miura, M. J. Org. Chem. 2009, 74, 6410. (j) Nakao, Y.;
Kashihara, N.; Kanyiva, K. S.; Hiyama, T. J. Am. Chem. Soc. 2008, 130,
16170. (k) Nakao, Y.; Kanyiva, K. S.; Hiyama, T. J. Am. Chem. Soc.
2008, 130, 2448. (l) Kanyiva, K. S.; Nakao, Y.; Hiyama, T. Angew.
Chem., Int. Ed. 2007, 46, 8872. (m) Liang, L.-C.; Chien, P.-S.; Huang, Y.-
L. J. Am. Chem. Soc. 2006, 128, 15562. (n) Nakao, Y.; Kanyiva, K. S.;
Oda, S.; Hiyama, T. J. Am. Chem. Soc. 2006, 128, 8146. (o) Chement, N.
D.; Cavell, K. J. Angew. Chem., Int. Ed. 2004, 43, 3845.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(14) For leading references on Cu-catalyzed C–H functionalization,
see: (a) Wang, Z.; Kuninobu, Y.; Kanai, M. Org. Lett. 2014, 16, 4790. (b)
Truong, T.; Klimovica, K.; Daugulis, O. J. Am. Chem. Soc. 2013, 135,
9342. (c) for a related review, see: Zhang, M. Appl. Organometal. Chem.
2010, 24, 269. (d) Do, H.-Q.; Kashif Khan, R. M.; Daugulis, O. J. Am.
Chem. Soc. 2008, 130, 15185.
(15) For a review on several first row transition metals, see: Kulkarni,
A. A.; Daugulis, O. Synthesis 2009, 4087.
(30) For an independent synthesis of a cobaltacycle, see reference 11e.
(16) (a) Nasonex (mometasone furoate), Zantac (ranitidine HCl),
lapatinib, and furadantin monohydrate are approved drugs containing a
furan moiety. Detailed information on these drug candidates including
compound structure, bioactivity, published studies, and information
regarding ongoing clinical trials, applications, and usage can be obtained
R. Comprehensive Heterocyclic Chemistry III, 1st ed., Elsevier,
Amsterdam, 2008.
(17) (a) Niraparib and pazopanib are 2-substituted 2H-indazoles
currently in clinical trials. Detailed information on these drug candidates
including compound structure, bioactivity, published studies, and
information regarding ongoing clinical trials, applications, and usage can
leading references on pharmaceutical applications and syntheses of 2-
substituted 2H-indazoles, see: Genung, N. E.; Wei, L.; Aspnes, G. E. Org.
Lett. 2014, 16, 3114.
(18) For azobenzene C–H functionalization with Co(0) and Co(I)
complexes, see: (a) Halbritter, G.; Knoch, F.; Wolski, A.; Kisch, H.
Angew. Chem., Int. Ed. Engl. 1994, 33, 1603. (b) Klein, H.-F.; Helwig,
ACS Paragon Plus Environment